Metacrine Announces MET409 Receives FDA Fast Track Designation for the Treatment of NASH
SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced that the U.S …